NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis $6.97 -0.03 (-0.43%) Closing price 04:00 PM EasternExtended Trading$7.05 +0.08 (+1.18%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Achieve Life Sciences Stock (NASDAQ:ACHV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Achieve Life Sciences alerts:Sign Up Key Stats Today's Range$6.83▼$7.1350-Day Range$6.65▼$8.5352-Week Range$2.62▼$8.64Volume1.20 million shsAverage Volume1.46 million shsMarket Capitalization$717.21 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company Overview Achieve Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing cytisinicline, a plant-based investigational therapy intended to help adults quit smoking and address nicotine addiction. Cytisinicline is designed to act on nicotinic acetylcholine receptors in the brain, potentially reducing nicotine cravings and withdrawal symptoms while helping limit the satisfaction associated with smoking. The company’s primary development program is aimed at securing regulatory approval for cytisinicline in the United States. Achieve has evaluated the therapy in clinical studies involving adults who smoke cigarettes and has also investigated its potential use in helping people quit vaping or using other nicotine products. Cytisinicline has a history of use in certain countries outside the United States under different brand names, although Achieve is conducting its own clinical and regulatory development program for the U.S. market. Achieve Life Sciences is headquartered in Seattle, Washington, and its operations are centered on clinical development, regulatory activities and commercialization planning for cytisinicline. The company’s leadership includes Chief Executive Officer Rick Stewart, who has experience in the development and commercialization of pharmaceutical products.AI Generated. May Contain Errors. Read More Achieve Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreACHV MarketRank™: 2.75062246101 of 5 starsAchieve Life Sciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 538th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAchieve Life Sciences has a consensus price target of $15.50, representing about 122.4% upside from its current price of $6.97.Amount of Analyst CoverageAchieve Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Achieve Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.92) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 17.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Achieve Life Sciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.29% of the float of Achieve Life Sciences has been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 10.88, which indicates bearish sentiment.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 9.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentAchieve Life Sciences has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Achieve Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows7 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.Percentage Held by Insiders1.80% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by Institutions33.52% of the stock of Achieve Life Sciences is held by institutions.Read more about Achieve Life Sciences' insider trading history. Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACHV Stock News HeadlinesAchieve Life Sciences, Inc. Announces Appointment of Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsOctober 8, 2026 | marketscreener.comMAchieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsOctober 7, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 15 at 1:00 AM | InvestorPlace (Ad)Achieve Life Sciences Announces Granting of New Hire Inducement AwardsOctober 6, 2026 | globenewswire.comAchieve Life Sciences, Inc. Announces CFO Changes, Effective October 5, 2026October 1, 2026 | marketscreener.comMAchieve Life Sciences Appoints Benjamin Halladay As CFOOctober 1, 2026 | rttnews.comAchieve Life Sciences Names Benjamin Halladay CFOOctober 1, 2026 | marketscreener.comMAchieve Life Sciences Appoints Benjamin Halladay as Chief Financial OfficerOctober 1, 2026 | globenewswire.comSee More Headlines ACHV Stock Analysis - Frequently Asked Questions How have ACHV shares performed this year? Achieve Life Sciences' stock was trading at $4.97 at the beginning of the year. Since then, ACHV stock has increased by 40.2% and is now trading at $6.97. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its earnings results on Tuesday, August, 11th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.64. When did Achieve Life Sciences' stock split? Achieve Life Sciences's stock reverse split before market open on Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Plug Power (PLUG), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA) and NIO (NIO). Company Calendar Last Earnings8/11/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ACHV's financial health is in the Green zone, according to TradeSmith. ACHV has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ACHV CIK949858 Webachievelifesciences.com Phone(425) 686-1500Fax425-686-1600Employees28Year Founded1995Price Target and Rating Average Price Target for Achieve Life Sciences$15.50 High Price Target$19.00 Low Price Target$12.00 Potential Upside/Downside+122.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-511.12% Return on Assets-82.35% Debt Debt-to-Equity Ratio0.87 Current Ratio0.95 Quick Ratio0.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book17.43Miscellaneous Outstanding Shares102,900,000Free Float101,050,000Market Cap$717.21 million OptionableOptionable Beta2.30 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ACHV) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
